Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Durvalumab (Imfinzi) immunotherapy
Durvalumab immunotherapy · 1 trial · 1 indication
Complete response and partial response evaluated by mRECIST.
| Arm | Type | Description |
|---|---|---|
| TheraSphere followed by Durvalumab and Tremelimumab | EXPERIMENTAL | TheraSphere followed by Tremelimumab plus Durvalumab administered once, then repeated administration of Durvalumab monthly up 18 months. |
| Name | Type | Description |
|---|---|---|
| TheraSphere Y-90 glass microsphere therapy | DEVICE | TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure. |
| Durvalumab (Imfinzi) immunotherapy | DRUG | 1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met: * Absence of clinical symptoms or signs indicating clinically significant disease progression * No decline in performance status * Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention * No other treatment discontinuation criteria are met |
| Tremelimumab immunotherapy | DRUG | 300 mg, single administration |
Inclusion Criteria: 1. Participants must be aged ≥18 years at the time of screening. 2. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and accountability Act in the US, European Union (EU) data privacy regulations in the EU) obtained from the pat...
Durvalumab immunotherapy is being studied for the treatment of Hepatocellular Carcinoma, a type of liver cancer. It is currently in Phase 2 clinical development for this indication. The drug is being evaluated in combination with other therapies to assess its safety and efficacy in patients with this condition.
Durvalumab immunotherapy is a monoclonal antibody, classified under the -mab target class. It is designed to target and modulate specific pathways involved in the immune response against cancer cells. In the context of Hepatocellular Carcinoma, it is being investigated for its potential to enhance the body's immune system to fight the tumor.
Durvalumab immunotherapy is being developed by Boston Scientific Corporation, a company traded on the stock exchange under the ticker symbol BSX. The company is conducting clinical trials to evaluate the drug's effectiveness in treating Hepatocellular Carcinoma.
Durvalumab immunotherapy is currently in Phase 2 clinical trials for Hepatocellular Carcinoma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 study is designed to gather more data on its safety and efficacy in patients.
Durvalumab immunotherapy is being evaluated in a Phase 2 clinical trial with the identifier NCT05063565. This study, titled 'TheraSphere With Durvalumab and Tremelimumab for HCC,' is actively recruiting participants and aims to enroll 100 patients with Hepatocellular Carcinoma. The trial is being conducted in the United States, France, Italy, Spain, and Switzerland.
Yes, Durvalumab immunotherapy is also known as Durvalumab (Imfinzi) immunotherapy. The drug is referred to by both names in clinical and research settings. This alternative name is used to identify the same investigational therapy being studied for Hepatocellular Carcinoma.